Age-Related Macular Degeneration

13 competing products in clinical development for Age-Related Macular Degeneration.

Pipeline by Phase

Pre-clinical1

Phase 13

Phase 24

Phase 33

Approved2

All Products (13)

Product	Company	Stage	Status	Hype
ASP7317 + tacrolimus + trimethoprim-sulfamethoxazole + Acyclovir + Nystatin	Astellas Pharma	Phase 1	Recruiting	36
E10030 plus Lucentis + Lucentis	Astellas Pharma	Phase 2	Completed	35
FYB203 2 mg (0.05 mL of 40 mg/mL)	Formycon AG	Approved	Completed	33
FYB201 0.5 mg (0.05 mL of 10 mg/mL)	Formycon AG	Approved	Completed	33
E10030 + ranibizumab + E10030 sham intravitreal injection	Astellas Pharma	Phase 3	Terminated	32
E10030 + bevacizumab or aflibercept + E10030 sham injection	Astellas Pharma	Phase 3	Terminated	32
E10030 + ranibizumab + E10030 sham intravitreal injection	Astellas Pharma	Phase 3	Terminated	32
volociximab	Astellas Pharma	Phase 1	Completed	29
E10030	Astellas Pharma	Phase 1	Completed	29
Fovista® + bevacizumab + ranibizumab + aflibercept	Astellas Pharma	Phase 2	Terminated	27
Sub-retinal transplantation of MA09-hRPE cells + tacrolimus and mycophenolate mofetil + Placebo tacrolimus and mycophenolate mofetil	Astellas Pharma	Phase 2	Withdrawn	27
Fovista® (anti-PDGF BB) plus anti-VEGF	Astellas Pharma	Phase 2	Terminated	27
MA09-hRPE	Astellas Pharma	Pre-clinical	Completed	26